Skip to main content

Table 4 Number of people recommended for treatment by QRISK3 and CRISK-CCI, observed event rate, and estimated number needed to treat to prevent an incident CVD event

From: Predictive performance of a competing risk cardiovascular prediction tool CRISK compared to QRISK3 in older people and those with comorbidity: population cohort study

Risk threshold

Number recommended for treatment

(% of all people)

Number of CVD

events

(% of all events)

NNT to prevent 1 CVD event*

Women

20%

   

  QRISK3

39219 (7.9%)

6084 (47.0%)

25.8

  CRISK-CCI

31,811 (6.4%)

5344 (41.2%)

23.9

10%

   

  QRISK3

79,825 (16.1%)

8849 (68.3%)

36.1

  CRISK-CCI

73,029 (14.8%)

8542 (65.9%)

34.2

7.5%

   

  QRISK3

100,396 (20.3%)

9718 (75.0%)

41.3

  CRISK-CCI

93,855 (19.0%)

9498 (73.3%)

39.5

Men

20%

   

  QRISK3

48,769 (10.3%)

7350 (45.1%)

26.5

  CRISK-CCI

41,517 (8.8%)

6125 (37.6%)

27.1

10%

   

  QRISK3

112,632 (23.8%)

11,620 (71.3%)

38.8

  CRISK-CCI

107,371 (22.7%)

11,272 (69.1%)

38.1

7.5%

   

  QRISK3

143,424 (30.3%)

12,967 (79.5%)

44.2

  CRISK-CCI

138,352 (29.2%)

12,703 (77.9%)

43.6

  1. *Assuming a 25% risk reduction with primary prevention statin treatment taken by all people recommended for treatment. NNT number needed to treat with statins. CVD cardiovascular disease